The Role of Targeted Therapy in Head and Neck Cancer

Targeted therapy is a personalized form of cancer treatment that focuses on specific molecules and pathways responsible for tumor growth, invasion, and metastasis. Unlike conventional chemotherapy, which affects all rapidly dividing cells, targeted therapy acts on cell-surface receptors, intracellular signaling proteins, or immune checkpoints, thereby limiting systemic toxicity.

Recent therapeutic strategies in head and neck squamous cell carcinoma (HNSCC) include EGFR inhibitors, immune checkpoint inhibitors (PD‑1/PD‑L1 blockers), and personalized genomic‑guided treatments. These approaches have transformed the management of locally advanced, recurrent, and metastatic disease.

Treatment Options for Head and Neck Cancer

Treatment Options for Head and Neck Cancer

Systemic (Precision) Therapies

• •EGFR inhibitors
  Block EGFR overexpression, seen in 80–90% of HNSCCs, to halt cell proliferation and angiogenesis.
• •Immune checkpoint inhibitors (PD‑1/PD‑L1)
  Reactivate the immune system to recognize and eliminate cancer cells.
• •Angiogenesis inhibitors and molecular therapies
  Investigational agents (like VEGF inhibitors) remain under study for recurrent or metastatic disease.

These agents may be used as monotherapy in frail or previously treated patients or combined with radiation and/or chemotherapy for synergistic results.

Mechanism of Action Overview

• •EGFR receptor (Cetuximab)
  Inhibits ligand binding & downstream signaling pathways; Used combined with radiation and/or chemotherapy for locally advanced disease.
• •EGFR‑TKIs (Afatinib, Erlotinib)
  Inhibit intracellular tyrosine kinase domain; Used in selected advanced/recurrent cases.
• •PD‑1/PD‑L1 checkpoint (Pembrolizumab, Nivolumab)
  Restore immune recognition of tumor cells; Used in recurrent/metastatic HNSCC.
• •VEGF/VEGFR (Bevacizumab (experimental))
  Blocks tumor blood‑vessel formation; Used in investigational settings or clinical trials.

Radiation and Targeted Therapy Integration

Combining targeted therapy with radiotherapy enhances local control by sensitizing tumors while protecting normal tissue.

• •Cetuximab + IMRT
  Standard combination for patients intolerant to cisplatin.
• •Pembrolizumab + RT
  Being investigated for HPV‑positive oropharyngeal cancers to enable dose reduction and immune co‑activation.

Therapy Guidelines for Head and Neck Cancer

NCCN/ESMO Recommendations

• •Locally advanced (Stage III–IV)
  Cetuximab + RT recommended when patients cannot receive cisplatin. Cisplatin + RT remains the first‑line standard if tolerated.
• •Recurrent/Metastatic disease
  Pembrolizumab or nivolumab as first‑line if PD‑L1 CPS ≥ 1. Pembrolizumab + platinum ± 5‑FU preferred in symptomatic or bulky disease.
• •Refractory/relapsed cases
  Enrolment in clinical trials or use of novel combination regimens (immunotherapy ± targeted agents).

How Guidelines Influence Your Plan

• •Molecular profiling
  (EGFR, PD‑L1, HPV/EBV testing)
• •Review of comorbidities and performance status
• •Discussion in a multidisciplinary tumor board
  To ensure precise, evidence‑based therapy choice.

Quality & Safety Monitoring

Quality & Safety Monitoring

• •Baseline liver, renal, and cardiac screening
  Before each cycle.
• •Weekly toxicity evaluation
  During active therapy.
• •Real‑time monitoring of adverse effects
  Like rash, hypomagnesemia, cytopenias, or immune‑related inflammation.

Common Drug Classes & Indications

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

• •EGFR monoclonal antibody (Cetuximab)
  Concurrent RT or first‑line palliative therapy.
• •Immune checkpoint inhibitors (Pembrolizumab, Nivolumab)
  PD‑1 blockade for R/M HNSCC.
• •TKIs (EGFR‑specific) (Afatinib, Erlotinib)
  Refractory or biomarker‑driven cases.
• •VEGF inhibitors (Bevacizumab)
  Investigational in combination settings.

Side‑ Effect Management & Support

• •Skin rash / acneiform dermatitis
  Topical steroids, doxycycline prophylaxis.
• •Diarrhea (TKIs)
  Loperamide, oral rehydration.
• •Electrolyte imbalance (Mg/K loss)
  IV electrolyte replacement.
• •Immune toxicities (pneumonitis, hepatitis)
  High‑dose corticosteroids, therapy hold.
• •Fatigue / infusion reactions
  Antihistamines, hydration, slow‑rate infusions.

Access Programs & Biosimilars

Everhope offers biosimilars of cetuximab and assists eligible patients through manufacturer and government‑funded programs for immunotherapy access and cost reduction.

Categories of Targeted Therapy Based on Tumor Biology

• •HPV‑Positive Oropharyngeal Cancer
  Excellent response to immunotherapy upon recurrence. Ongoing trials explore reduced‑dose RT + pembrolizumab for functional preservation.
• •EBV‑Associated Nasopharyngeal Carcinoma
  Demonstrates synergy of RT + cisplatin + immune‑checkpoint inhibitors. Plasma EBV DNA serves as an effective marker for treatment monitoring.
• •EGFR‑Overexpressed Oral & Hypopharyngeal Cancers
  Cetuximab + RT or cetuximab + platinum chemotherapy achieves favorable control in inoperable or recurrent cases.

Why Choose Everhope for Targeted Therapy in Head and Neck Cancer

• •Multidisciplinary Tumor Board & Expert Review
  Cases are evaluated by medical and radiation oncologists, molecular pathologists, radiologists, and pharmacists to ensure biomarker‑guided therapy selection.
• •Evidence‑Based Protocols & Quality Oversight
  Full compliance with NCCN v2.2025 and ESMO 2024 standards. On‑site testing for PD‑L1 CPS, EGFR expression, mutation profiling. Interim imaging every 8–12 weeks to assess treatment response.
• •Patient Safety & Supportive Coordination
  Pre‑infusion evaluation and observation for infusion reactions. 24×7 nursing hotline for real‑time management of toxicities. Counselling for skin care, oral hygiene, and immune‑related side effects.

Targeted Therapy Cost in Gurgaon for Head & Neck Cancer

What Influences Cost

Type and dosage of drug (cetuximab, pembrolizumab, nivolumab), dosing frequency (weekly, every 3–6 weeks), duration of therapy and cost of molecular testing/supportive meds.

Transparent Estimate Ranges

• •Cetuximab + RT (Weekly × 6–7 weeks)
  ₹ 2.5 – 3.5 L
• •Pembrolizumab Monotherapy (Every 3 weeks)
  ₹ 3 – 6 L per cycle
• •Nivolumab Monotherapy (Every 2–4 weeks)
  ₹ 2 – 4 L per cycle

Prices may vary depending on body weight, insurance coverage, and access program eligibility.

Insurance & Access Options

• •Cashless services
  With 25+ partner insurers.
• •EMI options
  Through oncology financing plans.
• •Participation in national compassionate‑use schemes
  For immunotherapy.

Targeted Therapy Treatment Process at Everhope

• •Step 1 – Consult & Molecular Work‑Up
  Comprehensive oncology consult with review of biopsy reports. Molecular tests: PD‑L1, HPV, EGFR, EBV DNA. Tumor board review and plan finalization within 48 hours.
• •Step 2 – Personalised Plan & Consent
  Selection of regimen (e.g., cetuximab vs pembrolizumab). Detailed explanation of dosing, goals, and potential toxicity. Financial counselling and informed consent.
• •Step 3 – Therapy Delivery & Monitoring
  Day‑care infusions under constant supervision. Continuous vital‑sign and toxicity monitoring. Imaging every 8–12 weeks to track response.
• •Step 4 – Follow‑Up, Survivorship & Rehabilitation
  Regular visits for immune‑related adverse event monitoring. Integration with nutrition, physiotherapy, speech, and psycho‑oncology for holistic recovery.